Showing 601 - 620 results of 48,349 for search '(( 50 ((we decrease) OR (a decrease)) ) OR ( 5 ((mg decrease) OR (mean decrease)) ))', query time: 1.15s Refine Results
  1. 601
  2. 602
  3. 603
  4. 604
  5. 605

    Inclusion of TPP side chains result in decreased melanoma cell mitochondria membrane potential, oxygen consumption, and increased DHE oxidation. by Kyle C. Kloepping (9928265)

    Published 2020
    “…At the 25 min mark, 1.0 μM 12-TPP was added to treatment A375 cells followed by the sequential addition of 2.5 μM oligomycin at the 60 min mark, 0.3 μM oligomycin at the 90 min mark, and 5.0 μM rotenone/antimycin A at the 120 min mark. …”
  6. 606
  7. 607
  8. 608

    There is a significant decrease in fibroblast, α-SMA, and Ly6C staining accompanied with a decrease in proliferation, and increase in cell death in the outflow vein removed <i>Iex-... by Akshaar Brahmbhatt (551498)

    Published 2014
    “…There is a significant decrease in the mean Fsp-1 staining in the <i>Iex-1</i> KO animals when compared to WT controls (P<0.05). …”
  9. 609
  10. 610
  11. 611
  12. 612
  13. 613
  14. 614
  15. 615
  16. 616
  17. 617
  18. 618

    Proliferative tissue degeneration is accompanied by a sustained decrease in proliferation, acute apoptotic responses, and progressive accumulation of DDR foci. by Catarina M. Henriques (102294)

    Published 2013
    “…Proliferative tissues such as A) testes, B) head kidney and C) gut sections show sustained significant decrease in proliferation in <i>tert<sup>−/−</sup></i> as compared to <i>tert<sup>+/+</sup></i> siblings (panels b, d and e) (p<0.001) and an acute apoptotic response at 3 months of age (p<0.001), which clears by c. 12 months (panels g, i and j). …”
  19. 619

    Mean SARS-CoV-2 viral load log 10 between groups. by Bruno Martins Tomazini (6509528)

    Published 2024
    “…</p><p>Results</p><p>From September 25, 2021, to February 3, 2022, 153 patients were randomized. The mean decay rate in SARS-CoV-2 viral load log<sub>10</sub> within 10 days was -3.75 (95% CI, -4.11; -3.19) in the placebo group, -3.83 (95% CI, -4.40; -2.27) in the halofuginone 0.5mg group and -4.13 (95% CI, -4.69; -3.57) in the halofuginone 1mg group, with no statistically significant difference in between placebo vs. halofuginone 0.5mg (mean difference -0.08; 95% CI -0.82 to 0.66, p = 0.96) and between placebo vs. halofuginone 1mg (mean difference -0.38; 95% CI, -1.11; 0.36, p = 0.41). …”
  20. 620